オプションチェーンは、Aytu BioPharmaの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Aytu BioPharmaの市場センチメントを評価します。.

Aytu BioPharma (NASDAQ:AYTU) 株価情報, オプションチェーン

Aytu BioPharma

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Aytu BioPharma Inc

The State of Wisconsin Investment Board (SWIB) has <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38988769/wisconsin-becomes-the-first-state-to-buy-bitcoin-btc-these-3-states-may-be-next">fully divested its position</a> in BlackRock's iShares Bitcoin Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>), a move confirmed in an SEC filing on May 15.
The liquidation of its entire 6 million-share stake, worth over $300 million, was <a href="https://www.sec.gov/Archives/edgar/data/854157/000106299325009484/xslForm13F_X02/form13fInfoTable.xml">completed</a> by March 31, just before the start of a volatile quarter marked by intensifying global trade tensions.
The timing of the sale is notable. 
It came two days before "Liberation Day" on April 2, when the U.S. implemented sweeping tariffs that upended global trade. 
The policy marked a dramatic escalation in President Donald Trump's efforts to reshape American trade by encouraging domestic manufacturing and penalizing foreign imports.
Throughout February and March, the White House introduced a flurry of tariffs: 25% on Canadian and Mexican goods (later paused), a 10% duty on Chinese imports, and increased levies on steel and aluminum. 
The standoff reached a boiling point in March, when U.S. tariffs on Chinese goods hit 145%, prompting Beijing to retaliate with 125% tariffs on U.S. products.
Also Read: <a href="https://www.benzinga.com/markets/25/05/45457978/3-key-drivers-behind-ethereums-65-rally-bernstein">3 Key Drivers Behind Ethereum&#8217;s 65% Rally: Bernstein</a>
Amid this tit-for-tat escalation, financial markets responded with turbulence. 
At the height of tariff retaliation, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) sank below $75,000.
By mid-May, signs of de-escalation emerged. 
Both the U.S. and China agreed to temporarily reduce tariffs, with the U.S. lowering rates on Chinese goods to 30% and China dropping its own tariffs to 10%. 
Trump also suspended most reciprocal tariffs on other allies.
SWIB's decision to offload its Bitcoin ETF holdings before this policy storm suggests the fund was seeking to reduce exposure to risk assets amid macroeconomic uncertainty.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45457965/3-key-drivers-behind-ethereums-65-rally-bernstein">Eric Trump: Bitcoin Accumulation Is &#8216;A Race To The Top&#8217;</a> 
<div class="flex flex-col w-full items-start lg:flex-row" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; display: flex; width: 770px; flex-direction: row; align-items: flex-start; color: rgb(45, 45, 45); font-family: Manrope, Manrope-fallback, sans-serif; font-size: 16px; white-space-collapse: collapse; background-color: rgb(25, 41, 64);">
<div class="sc-hWsrZR hMcqgd article-submitted flex flex-grow" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; display: inline-block; flex-grow: 1; font-size: 14px; margin-bottom: 0.3rem;">
<div class="article-submitted-content flex-wrap" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; flex-wrap: wrap;">
<div class="article-author-wrap flex items-center gap-1 text-gray-300" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; display: flex; align-items: center; gap: 0.25rem; --tw-text-opacity: 1; color: rgb(209, 213, 219);"><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></div>
</div>
</div>
</div>
</li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

$ETH

IBIT

Wisconsin Pension Fund Exits $300M Bitcoin ETF Position

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) with a Buy and maintains $20 price target.

Price Target

Reiteration

Analyst Ratings

ACOG

HC Wainwright & Co. Reiterates Buy on Alpha Cognition, Maintains $20 Price Target

Citigroup analyst Michael Rollins reinstates Uniti Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNIT#NASDAQ">UNIT</a>) with a Neutral and announces $5.3 price target.

Initiation

UNIT

Citigroup Reinstates Neutral on Uniti Group, Announces $5.3 Price Target

HC Wainwright &amp; Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) with a Buy and lowers the price target from $44 to $41.

BCAX

HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Lowers Price Target to $41

HC Wainwright &amp; Co. analyst Robert Burns reiterates TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) with a Buy and maintains $12 price target.

HURA

HC Wainwright & Co. Reiterates Buy on TuHURA Biosciences, Maintains $12 Price Target

ECARX Unveils EXP01 RISC-V Processor At Summit In Paris, Advances Next-Gen MCU Roadmap And Deepens Ecosystem Ties For Smart Mobility

Needham analyst Joshua Reilly reiterates Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) with a Buy and maintains $125 price target.

TWLO

Needham Reiterates Buy on Twilio, Maintains $125 Price Target

ATA Creativity Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AACG#NASDAQ">AACG</a>) raises FY2025 sales outlook from $37.81 million-$38.50 million to $38.03 million-$38.72 million.

Guidance

AACG

ATA Creativity Global Raises FY2025 Sales Guidance from $37.81M-$38.50M to $38.03M-$38.72M

Barclays analyst Adrienne Yih downgrades Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) from Overweight to Equal-Weight and raises the price target from $14 to $24.

Downgrades

Barclays Downgrades Foot Locker to Equal-Weight, Raises Price Target to $24

NGNE

Neurogene Announces Evidence-Based Monitoring And Treatment Intended To Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV

ATA Creativity Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AACG#NASDAQ">AACG</a>) reported quarterly losses of $(0.06) per share. This is a 25 percent increase over losses of $(0.08) per share from the same period last year. The company reported $7.69 million in sales this quarter. This is a 15.35 percent increase over sales of $6.67 million the same period last year.

Earnings

ATA Creativity Glb Q1 Adj. EPS $(0.06) Up From $(0.08) YoY, Sales $7.69M Up From $6.67M YoY

Management

Novo Nordisk CEO Lars Fruergaard Jørgensen To Step Down, Search For Successor Is Ongoing; Lars Fruergaard Jørgensen Will Continue As CEO For A Period Amid Transition

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBIO#NASDAQ">ZBIO</a>) with a Buy and maintains $30 price target.

ZBIO

HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $30 Price Target

<a href="https://www.globenewswire.com/Tracker?data=BkCKt-Jh3o9pFkwpuXgGU5ejQK8a8a-6BBr8QPEWbezjCS3HSbIn6MZu2BrF3K4-6CNVWvAz87mz5l-J-QHkTCGuDJhNwh27kKWJUW2V__orBgkeKeVWnIdL6QKzKArS">BioCryst Pharmaceuticals, Inc.</a> (Nasdaq:&nbsp;BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO&#xAE; (berotralstat) in adolescents and people with severe HAE showing significant and sustained reductions in HAE attack rates through 18 months of follow-up after beginning treatment with ORLADEYO in both patient populations.
The real-world evidence was presented in two posters at the 2025 International Society for Pharmacoeconomics and Outcomes Research conference (ISPOR), which is being held in Montreal from May 13-16, 2025.

BCRX

BioCryst Pharma Presents New Real-World Evidence Showing ORLADEYO Delivers Sustained HAE Attack Reduction in Adolescents & Severe Cases

As ValueAct Holdings, LP. buys a fresh stake in Rocket Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>), Andrew Left&#8216;s Citron Research endorses the move, calling the investment a &#8220;multi-year story.&#8221;
What Happened: The co-CEO and CIO of ValueAct, Mason Morfit, added 6.728 million shares worth $81.213 million to its portfolio during the first quarter, according to its 13F filings.
The company represented 1.8% of ValueAct&#8217;s total holdings as of the first quarter.
However, Rocket&#8217;s recent SEC filing dated May 15 showed that ValueAct held 15.125 million shares in the company, representing 9.9% of the total stake.
Citron Research cited this in an X post and lauded the co-CEO, Morfit, for being the &#8220;most strategic, long-term thinkers&#8221; and stating that he is one of the minds who reshaped Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) from the boardroom. 
&#8220;When someone like that sees $RKT as a compounder, it's not about quarterly noise—it's the start of a multi-year story,&#8221; said Citron&#8217;s post.
Highlighting Morfit&#8217;s comments, it added, &#8220;The CEO called Rocket a &#8216;sleeping giant&#8217; in its &#8216;early innings&#8217; yesterday,&#8221; the post added.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24RKT&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$RKT</a> – Game on. ValueAct just filed a 10% stake. Mason Morfit isn't just any investor—he's the mind who reshaped Microsoft from the boardroom. Citron has been active on Wall Street for 25+ years, and Morfit remains one of the most strategic, long-term thinkers we've ever met.…
&mdash; Citron Research (@CitronResearch) <a href="https://twitter.com/CitronResearch/status/1923119403777786252?ref_src=twsrc%5Etfw">May 15, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/market-summary/25/05/45399940/warren-buffett-shows-how-patience-pays-98-of-his-160-billion-wealth-came-after-turning-65-thanks-the-power-of-compound-interest">Warren Buffett Shows How Patience Pays: 98% Of His $160 Billion Wealth Came After Turning 65, Thanks The Power Of &#8216;Compound Interest&#8217;</a>
Why It Matters: Apart from Rocket Companies, ValueAct&#8217;s 13F filings showed 13 more companies that the firm held a stake in, after the first quarter. Here is a list of all its holdings.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Holdings As Of Q1</td>
<td>Stake</td>
<td>Value (In Million)</td>
</tr>
<tr>
<td>Salesforce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>)</td>
<td>17%</td>
<td>$777.84</td>
</tr>
<tr>
<td>Walt Disney Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>)</td>
<td>14%</td>
<td>$648.07</td>
</tr>
<tr>
<td>Insight Enterprises Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSIT#NASDAQ">NSIT</a>)</td>
<td>13%</td>
<td>$609.22</td>
</tr>
<tr>
<td>Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</td>
<td>13%</td>
<td>$584.93</td>
</tr>
<tr>
<td>Roblox Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>)</td>
<td>11%</td>
<td>$510.91</td>
</tr>
<tr>
<td>Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>)</td>
<td>10%</td>
<td>$460.14</td>
</tr>
<tr>
<td>Liberty Media Corp. Series C (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LLYVK#NASDAQ">LLYVK</a>)</td>
<td>5.80%</td>
<td>$266.01</td>
</tr>
<tr>
<td>Expedia Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>)</td>
<td>4.10%</td>
<td>$187.79</td>
</tr>
<tr>
<td>Live Nation Entertainment Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>)</td>
<td>2.50%</td>
<td>$115.60</td>
</tr>
<tr>
<td>Liberty Media Corp. Series A (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LLYVA#NASDAQ">LLYVA</a>)</td>
<td>2.40%</td>
<td>$111.53</td>
</tr>
<tr>
<td>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>2.30%</td>
<td>$107.14</td>
</tr>
<tr>
<td>Toast Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>)</td>
<td>1.90%</td>
<td>$86.15</td>
</tr>
<tr>
<td>Rocket Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>)</td>
<td>1.80%</td>
<td>$81.21</td>
</tr>
<tr>
<td>Nu Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>)</td>
<td>0.80%</td>
<td>$34.98</td>
</tr>
</tbody>
</table>
</figure>
Price Action: Shares of RKT rose 1.35% on Thursday. The stock was up 17.70% on a year-to-date basis, but 8% lower over a year. It was trading nearly 6% higher during the premarket session on Friday.
Benzinga Edge Stock Rankings shows that RKT had a stronger price trend over the short and the medium term but a weaker trend over the long term. Its momentum ranking was moderate at the 37.21th percentile. You can check the details of other metrics <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">over here</a>. 
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="147" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16064327/RKT-EDGE-1024x147.png" alt="" class="wp-image-917733" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16064327/RKT-EDGE-1024x147.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16064327/RKT-EDGE-300x43.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16064327/RKT-EDGE-768x110.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/16064327/RKT-EDGE.png 1219w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Friday. The SPY was up 0.24% to $591.85, while the QQQ advanced 0.24% to $520.50, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/market-summary/25/05/45461488/walmart-e-commerce-turns-profitable-for-the-first-time-despite-reduced-tariffs-ceo-says-full-impact-cant-be-absorbed-price-hikes-likely">Walmart E-Commerce Turns Profitable For The First Time: Despite Reduced Tariffs, CEO Says Full Impact Can&#8217;t Be Absorbed, Price Hikes Likely</a></li>
</ul>
Image Via Shutterstock

Equities

Market Summary

Broad U.S. Equity ETFs

Futures

Hedge Funds

Markets

ETFs

General

AMZN

EXPE

LLYVA

LLYVK

MSFT

NSIT

RBLX

TOST

Rocket Companies Soars 6% In Friday Premarket As Activist Investor ValueAct Reveals New Position, Calls RKT A 'Sleeping Giant' In Early Innings

Longbow Research analyst David Macgregor initiates coverage on HNI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HNI#NYSE">HNI</a>) with a Buy rating and announces Price Target of $70.

Longbow Research Initiates Coverage On HNI with Buy Rating, Announces Price Target of $70

Flowers Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLO#NYSE">FLO</a>) lowers FY2025 Adj EPS guidance from $1.18-$1.28 to $1.05-$1.15 vs $1.16 analyst estimate. Lowers FY2025 sales outlook from $5.18 billion-$5.26 billion to $5.08 billion-$5.17 billion vs $5.41 billion estimate.

FLowers Foods Lowers FY2025 Adj EPS Guidance from $1.18-$1.28 to $1.05-$1.15 vs $1.16 Est; Lowers FY2025 Sales, Excluding the Simple Mills acquisition Guidance from $5.18B-$5.26B to $5.08B-$5.17B vs $5.41B Est

WIIM

ORGN

Origin Materials shares are trading lower after the company reported a year-over-year decrease in Q1 financial results and cut its FY26 sales guidance below estimates.

GLOB

Globant shares are trading lower after the company reported worse-than-expected Q1 financial results, issued Q2 guidance below estimates, and cut its FY25 guidance.

LGCY

Legacy Education shares are trading higher after the company reported better-than-expected Q3 financial results.

Press Releases

Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

Aytu BioPharma Disclosure Notification

Events

Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results

Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results

Comments

Aytu BioPharma

Aytu BioPharma (AYTU) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル